Kengo Nagashima, Ph.D.

Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital.
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
E-mail:
Website: https://nshi.jp/en/

• Tokyo University of Science, Ph.D., Engineering, 2014
• Tokyo University of Science, M.Sc., Engineering, 2008
• Tokyo University of Science, B.Sc., Engineering, 2006

• Project Associate Professor, Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, April 2021–present.
• Project Associate Professor, Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, April 2018–March 2021.
• Research Assistant Professor, Department of Global Clinical Research, Graduate School of Medicine, Chiba University, April 2015–March 2018.
• Research Assistant Professor, Clinical Research Center, Chiba University Hospital, April 2013–March 2015.
• Research Associate, Faculty of Pharmaceutical Sciences, Josai University, April 2008–March 2013.

Part-time / Visiting Positions

• Lecturer (part-time), Akita University Graduate School of Medicine, April 2024–present.
• Visiting Scientist, Division of Cancer Therapeutics, National Cancer Center Research Institute, July 2023–present.
• Lecturer (part-time), Nippon Medical School, April 2021–present.
• Lecturer (part-time), Graduate School of Engineering, Tokyo University of Science, April 2016–present.
• Visiting Scientist, Department of Translational Oncology, National Cancer Center Research Institute, November 2021–October 2022.
• Visiting Associate Professor, Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, April 2021–March 2023.
• Visiting Scientist, Department of Biomarkers for the Early Detection of Cancer, National Cancer Center Research Institute, September 2019–August 2021.
• Lecturer (part-time), Keio University School of Medicine, April 2019–March 2021.

Statistical Methodology and Applications in Biostatistics

1. Gosho M, Ryota Ishii R, Nagashima K, Noma H, Maruo K. Determining the prior mean in Bayesian logistic regression with sparse data: A non-arbitrary approach. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2024. In press. DOI: 10.1093/jrsssc/qlae048.
2. Kimura R, Nomura S, Nagashima K, Sato Y. Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method. BMC Medical Research Methodology 2024;24(1):166. DOI: 10.1186/s12874-024-02295-2.
3. Gosho M, Ohigashi T, Nagashima K, Ito Y, Maruo K. Bias in odds ratios from logistic regression methods with sparse data set. Journal of Epidemiology 2023;33(6):265–275. DOI: 10.2188/jea.JE20210089.
4. Noma H, Nagashima K, Kato S, Teramukai S, Furukawa TA. Flexible random-effects distribution models for meta-analysis. Journal of Epidemiology 2022;32(10):441–448. DOI: 10.2188/jea.JE20200376. [arXiv:2003.04598]
5. Hamaguchi Y, Noma H, Nagashima K, Yamada T, Furukawa TA. Frequentist performances of Bayesian prediction intervals for random-effects meta-analysis. Biometrical Journal 2021;63(2):394–405. DOI: 10.1002/bimj.201900351. [arXiv:1907.00345]
6. Nagashima K, Noma H, Sato Y, Gosho M. Sample size calculations for single-arm survival studies using transformations of the Kaplan–Meier estimator. Pharmaceutical Statistics 2021;20(3):499–511. DOI: 10.1002/pst.2090. [arXiv:2012.03355]
7. Noma H, Nagashima K, Furukawa TA. Permutation inference methods for multivariate meta-analysis. Biometrics 2020;76(1):337–347. DOI: 10.1111/biom.13134. [arXiv:1809.03935]
8. Nagashima K, Noma H, Furukawa TA. Prediction intervals for random-effects meta-analysis: a confidence distribution approach. Statistical Methods in Medical Research 2019;28(6):1689–1702. DOI: 10.1177/0962280218773520. [arXiv:1804.01054] [Software]
9. Noma H, Nagashima K, Maruo K, Gosho M, Furukawa TA. Bartlett-type corrections and bootstrap adjustments of likelihood-based inference methods for network meta-analysis. Statistics in Medicine 2018;37(7):1178–1190. DOI: 10.1002/sim.7578.
10. Sato Y, Gosho M, Nagashima K, Takahashi S, Ware JH, Laird NM. Statistical methods in the Journal — an update. New England Journal of Medicine 2017;376(11):1086–1087. DOI: 10.1056/NEJMc1616211. (Correspondence)
11. Nagashima K, Sato Y. Information criteria for Firth's penalized partial likelihood approach in Cox regression models. Statistics in Medicine 2017;36(21):3422–3436. DOI: 10.1002/sim.7368. [Postprint]
12. Nagashima K, Sato Y, Noma H, Hamada C. An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach. Statistics in Medicine 2013;32(27):4838–4858. DOI: 10.1002/sim.5895. [arXiv:1805.05017]
13. Nagashima K, Sato Y, Hamada C. A modified maximum contrast method for unequal sample sizes in pharmacogenomic studies. Statistical Applications in Genetics and Molecular Biology 2011;10(1):Article 41. DOI: 10.2202/1544-6115.1560. [Postprint] [Software]

Medical Researches

14. Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Rika Kizawa R, Muro K, Aoki K, Boku N. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). Journal for ImmunoTherapy of Cancer 2024;12(11):e010174. DOI: 10.1136/jitc-2024-010174.
15. Inoue M, Ogasawara S, Kobayashi K, Okubo T, Itokawa N, Obu M, Fujimoto K, Unozawa H, Yumita S, Fujiwara K, Nakagawa M, Kanzaki H, Koroki K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakamoto S, Nagashima K, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Kato N. Assessment of macrovascular invasion in advanced hepatocellular carcinoma: clinical implications and treatment outcomes with systemic therapy. Liver Cancer 2024. In press. DOI: 10.1159/000539380.
16. Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M, Tsuruoka N, Kasai T, Hata A. Effectiveness of self-sampling human papillomavirus test on pre-cancer detection and screening uptake in Japan: The ACCESS randomized controlled trial. International Journal of Cancer 2024;155(5):905–915. DOI: 10.1002/ijc.34970.
17. Okui J*, Nagashima K*, Matsuda S*, Sato Y, Okamura A, Kawakubo H, Muto M, Kakeji Y, Kono K, Takeuchi H, Watanabe M, Doki Y, Bamba T, Fukuda T, Fujiwara H, Sato S, Noma K, Miyata H, Fujita T, Kitagawa Y. Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. British Journal of Surgery 2024;111(2):znae038. DOI: 10.1093/bjs/znae038.
18. Kashiro A, Kobayashi M, Oh T, Miyamoto M, Atsumi J, Nagashima K, Takeuchi K, Nara S, Hijioka S, Morizane C, Kikuchi S, Kato S, Kato K, Ochiai H, Obata D, Shizume Y, Konishi H, Nomura Y, Matsuyama K, Xie C, Wong C, Huang Y, Jung G, Srivastava S, Kutsumi H, Honda K. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Journal of Gastroenterology 2024; 59(3): 263–278. DOI: 10.1007/s00535-023-02072-w.
19. Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Morooka M, Ogushi M, Nagashima K, Sato Y, Kuriyama N, Kuwabara S. Prevalence, clinical profiles, and prognosis of CIDP in Japanese nationwide survey: analyses of 1257 diagnosis-confirmed patients. Neurology 2024;102(6):e209130. DOI: 10.1212/WNL.0000000000209130.
20. Kishimoto T, Kinoshita S, Kitazawa M, Hishimoto A, Asami T, Suda A, Bun S, Kikuchi T, Sado M, Takamiya A, Mimura M, Sato Y, Takemura R, Nagashima K, Nakamae T, Abe Y, Kanazawa T, Kawabata Y, Tomita H, Abe K, Hongo S, Kimura H, Sato A, Kida H, Sakuma K, Funayama M, Sugiyama N, Hino K, Amagai T, Takamiya M, Kodama H, Goto K, Fujiwara S, Kaiya H, Nagao K, on behalf of the J-PROTECT collaborators. Live two-way video versus face-to-face treatment for depression, anxiety, and obsessive-compulsive disorder: A 24-week randomized controlled trial. Psychiatry and Clinical Neurosciences 2024;78(3):220–228. DOI: 10.1111/pcn.13618.
21. Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, Kohno T, Yatabe Y, Kanemitsu Y, Hamamoto R, Takashima A, Shiraishi K, Sekine S. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer. British Journal of Cancer 2023;129(7):1176–1183. DOI: 10.1038/s41416-023-02382-z.
22. Uwamino Y*, Nagashima K*, Yoshifuji A, Suga S, Nagao M, Fujisawa T, Ryuzaki M, Takemoto Y, Namkoong H, Wakui M, Matsushita H, Hasegawa N, Sato Y, Murata M. Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination. npj Vaccines 2023; 8(1): 33. DOI: 10.1038/s41541-023-00626-w. (*equally contributed)
23. Matsumura T, Ebigbo A, Römmele C, Ikematsu H, Ishigami H, Suzuki T, Harada H, Yada T, Takatori Y, Takeuchi M, Okimoto K, Akizue N, Maruoka D, Kitagawa Y, Minamide T, Iwaki T, Amano Y, Matsusaka K, Nagashima K, Maehata T, Yahagi N, Messmann H, Kato N. Diagnostic value of adding magnifying chromoendoscopy to magnifying narrow-band imaging endoscopy for colorectal polyps. Clinical Gastroenterology and Hepatology 2023; 21(10): 2551–2559.e2 DOI: 10.1016/j.cgh.2023.01.028.
24. Yamaguchi Y, Takashima A, Nagashima K, Kumagai K, Yamada T, Terashima M, Yabusaki H, Nishikawa K, Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukagawa T, Kinoshita T, Watanabe M, Ishiyama K, Inoue K, Boku N. Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study. Gastric Cancer 2023;26(2):307–316. DOI: 10.1007/s10120-023-01363-8.
25. Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. Gastric Cancer 2023;26(1):132–144. DOI: 10.1007/s10120-022-01349-y.
26. Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Yatabe Y, Shida D, Hamamoto R, Kleeman SO, Leedham SJ, Maughan T, Takashima A, Shiraishi K, Sekine S. Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer. British Journal of Cancer 2022;127(6):1043–1050. DOI: 10.1038/s41416-022-01880-w.
27. Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Evolution of survival impact of molecular target agents in patients with advanced hepatocellular carcinoma. Liver Cancer 2022;11(1):48–60. DOI: 10.1159/000519868.
28. Felix K, Honda K, Nagashima K, Kashiro A, Takeuchi K, Kobayashi T, Hinterkopf S, Gaida MM, Dang H, Brindl N, Kaiser J, Büchler MW, Strobel O. Non-invasive risk stratification of IPMN with malignant potential by serum apolipoprotein-A2-isoforms. International Journal of Cancer 2022;150(5):881–894. DOI: 10.1002/ijc.33875.
29. Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Itoh M, Chen W-Y, Takano M, Yoshikawa T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayakawa N, Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O, Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe Y, Suematsu M. On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biology 2021;41:101926. DOI: 10.1016/j.redox.2021.101926.
30. Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, Tanaka R, Yamada T, Kinoshita T, Inada T, Ishiyama K, Ema A, Yuasa Y, Haruta S, Kakihara N, Nishikawa K, Yunome G, Satoh T, Fukagawa T, Katai H, Boku N. Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): A multi-institutional retrospective study. Gastric Cancer 2021;24(3):701–709. DOI: 10.1007/s10120-020-01137-6.
31. Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Ooka Y, Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer 2020;9(5):583–595. DOI: 10.1159/000508724.
32. Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, On behalf of the PRIME-V study group. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised controlled study (PRIME-V study). Diabetes, Obesity and Metabolism 2019;21(8):1990–1995. DOI: 10.1111/dom.13750.
33. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K-i, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, for the Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain–Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519–529. DOI: 10.1016/S1474-4422(18)30114-5.
34. Watanabe K, Hirano S, Kojima K, Nagashima K, Mukai H, Sato T, Takemoto M, Matsumoto K, Iimori T, Isose S, Omori S, Shibuya K, Sekiguchi Y, Beppu M, Amino H, Suichi T, Yokote K, Uno T, Kuwabara S, Misawa S. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. Journal of Neurology, Neurosurgery, and Psychiatry 2018;89(10):1082–1087. DOI: 10.1136/jnnp-2017-316601.
35. Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. Gastric Cancer 2018;21(3):439–445. DOI: 10.1007/s10120-017-0753-2.
36. Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. International Journal of Clinical Oncology 2018;23(2):382–388. DOI: 10.1007/s10147-017-1200-4.
37. Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer 2017;20(4):655–662. DOI: 10.1007/s10120-016-0670-9.
38. Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Akagi R, Yamaguchi T, Takahashi K, Nagashima K, Takahashi K. Quantitative US elastography can quantify mechanical and histological tendon healing in a rabbit model of achilles tendon transection. Radiology 2017;283(2):408–417. DOI: 10.1148/radiol.2016160695.
39. Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, Ikeda S-i, Kohara N, Kanda T, Kira J-i, Hanaoka H, Kuwabara S, for the Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2016;15(11):1129–1137. DOI: 10.1016/S1474-4422(16)30157-0.
40. Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunology Research 2016;4(7):592–599. DOI: 10.1158/2326-6066.CIR-15-0298.

Full publication list: Curriculum vitae (PDF)

1. Nagashima K, Noma H, Furukawa TA. pimeta: an R package of prediction intervals for random-effects meta-analysis. [arXiv:2110.07856]

Statistical Methodology

1. Nagashima K. pimeta: Prediction Intervals for Random-Effects Meta-Analysis. Evidence Synthesis and Meta-Analysis in R Conference (ESMARConf 2023), Mar. 27–31, 2023, Virtual. (Invited Lecture)
2. Nagashima K, Sato Y. Information criterion for Firth-type penalized partial likelihood in Cox regression. The 27th International Biometric Conference, Jul. 6–11, 2014; Firenze Fiera, Italy. (Poster) [Abstract]
3. Nagashima K, Sato Y, Hamada C. A high-speed method for population pharmacokinetic data analysis in genome-wide pharmacogenomic studies. The 26th International Biometric Conference, Aug. 26–31, 2012; Kobe Internatioanl Conference Center Kobe, Japan. (Poster) [Abstract]
4. Nagashima K, Sato Y, Hamada C. Studentized modified maximum contrast method for unequal sample sizes in pharmacogenomics studies. The 25th International Biometric Conference, Dec. 5-10, 2010; Federal University of Santa Catarina, Florianópolis, SC, Brazil. [Abstract]

Biostatistics

1. Statistical inference for random-effects meta-analyses under model misspecification. Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant-in-Aid for Young Scientists. April 2019–March 2022. Grant number: 19K20229. (PI)
2. Developments of statistical inference, prediction, and modeling methods for network meta-analysis. Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant-in-Aid for Scientific Research (B). April 2019–March 2020. Grant number: 19H04074. (Co-I)
3. Statistical inference for rare event data and its application in clinical researches. Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant-in-Aid for Young Scientists (B). April 2016–March 2019. Grant number: 16K16014. (PI)

Medical Researches

4. Development of in vitro diagnostics for precision medicine based on subtyping with pre-treatment biopsies of intractable esophageal cancer. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. October 2024–March 2027. (Co-I)
5. Development of blood biomarkers for risk stratification in pancreatic cancer and colorectal cancer. Japan Agency for Medical Research and Development, Project for Promotion of Cancer Research and Therapeutic Evolution. April 2024–March 2026. (Co-I)
6. Clinical development of blood biomarkers for malignant risk stratification from precancerous pancreatic lesions using estimation of pancreatic exocrine function. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. April 2024–March 2027. (Co-I)
7. Research to promote public awareness for supporting women's physical and mental health toward improving the healthy life expectancy. The Ministry of Health Labour and Welfare, Health Labour Sciences Research Grant. April 2023–March 2027. (Co-I)
8. Development of early detection biomarkers for gastroenterological cancer by antibody-based comprehensive screening. Japan Agency for Medical Research and Development, Project for Promotion of Cancer Research and Therapeutic Evolution (P-PROMOTE). April 2022–March 2024. (Co-I)
9. Clinical development of a diagnostic method for early-stage pancreatic cancer and risk factors for pancreatic cancer malignancy using a blood biomarker to evaluate a pancreatic exocrine function. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. April 2021–March 2024. (Co-I)
10. Study for clinical development of precision medicine for esophageal cancer. Japan Agency for Medical Research and Development, Project for Cancer Research and Therapeutic Evolution (P-CREATE). April 2021–March 2023. (Co-I)
11. Health literacy improvement of cervical cancer prevention using information and communications technology. Japan Society for the Promotion of Science (JSPS) KAKENHI, Challenging Research (Exploratory). July 2019–March 2022. Grant number: 19K22737. (Co-I)
12. Practical application of efficient pancreatic cancer screening with plasma biomarker. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. December 2018–March 2020. (Co-I)
13. Practical research of blood biomarkers for predicting effects of postoperative adjuvant chemotherapies by metastatic activity analysis of non-small cell lung cancer. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. April 2017–March 2020. (Co-I)
14. Developing an early-detection and risk-stratification biomarkers for cancer by analyzing post-translational modifications to proteins and peptides. Japan Agency for Medical Research and Development, Project for Cancer Research and Therapeutic Evolution (P-CREATE). April 2017–March 2022. (Co-I)
15. Evaluation study for efficacy and safety of drug therapy based on sex differences. Japan Agency for Medical Research and Development, Project for Whole Implementation to Support and Ensure the female life—Wise. November 2016–March 2019. (Co-I)
16. Development of efficient screening method for early detection and risk stratification of pancreatic cancer. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. September 2016–March 2017. (Co-I)

• Biostatistics and medical informatics, School of Medicine, Keio University, 2022–present.
• Public health II, School of Medicine, Keio University, 2022–present.
• Biostatistics, Graduate School of Health Management, Keio University, 2021–present.
• Design and analysis of clinical trials, Graduate School of Health Management, Keio University, 2019–present.
• Linear statistical inference, Graduate School of Engineering, Tokyo University of Science, 2016–present.
• Introduction of clinical research, Graduate School of Medical and Pharmaceutical Sciences, Chiba University, 2014.
• Principles of biostatistics, Graduate School of Medical and Pharmaceutical Sciences, Chiba University, 2010–2018.

• Member, American Statistical Association, 2011–present.
• Member, The International Biometric Society, 2008–present.

Statistics Journal

• Statistics in Medicine
• Statistical Methods in Medical Research
• Journal of the Royal Statistical Society: Series C (Applied Statistics)
• Biometrical Journal
• Research Synthesis Methods
• Annals of the Institute of Statistical Mathematics
• Statistics in Biopharmaceutical Research
• Japanese Journal of Statistics and Data Science
• Biostatistics & Epidemiology
• Entropy
• BMC Medical Research Methodology
• The Journal of Experimental Education
• Journal of the Royal Society Interface
• Distributed Ledger Technologies
• Journal of Statistical Computation and Simulation
• Statistical Applications in Genetics and Molecular Biology
• Contemporary Clinical Trials Communications
• BMC Bioinformatics
• Behaviormetrika
• Stats
• Mathematics

Medical Journal

• Nature Communications
• European Journal of Epidemiology
• BMJ Public Health
• Cancer Science
• Esophagus
• Diabetes, Obesity and Metabolism
• Aging
• Expert Review of Respiratory Medicine
• Epidemiology and Infection
• Sleep Medicine
• Trials
• PLoS ONE
• BMJ Open
• Nanomedicine
• Cancer Biomarkers
• Asia-Pacific Journal of Clinical Oncology
• Journal of Clinical Pharmacy and Therapeutics
• International Journal of Environmental Research and Public Health

• [R] RevGadgets Package as a contributor (postprocessing gadgets for output generated by RevBayes; CRAN Task View: Phylogenetics)
• [R] pimeta Package (prediction intervals for random-effects meta-analysis; Nagashima K, et al. SMMR 2019; CRAN Task View: MetaAnalysis)
• [R] ph2bayes Package (Bayesian Single-Arm Phase II Designs; CRAN Task View: ExperimentalDesign)
• [R] RcmdrPlugin.KMggplot2 Package (ggplot2 GUI frontend)
• [R] mmcm Package (Nagashima K, et al. SAGMB 2011)
• [SAS] %skmdata macro (SAS macro for Kaplan-Meier plots with SGPLOT Procedure)
• [Web App] Sample Size Calculator

•  ORCID (0000-0003-4529-9045)
•  Google Scholar Citations
•  ResearchGate
•  Publons (ResearcherID)
•  PubMed
•  GitHub